Wen-Pin Su - Concepedia

Author

Wen-Pin Su

National Cheng Kung University Hospital

Also Known As

Oleg Lipatov, W.-C. Su, WEIJUN SU, Wen-Pin SU, Wen-Pin Su

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

National Cheng Kung University Hospital Institut Gustave Roussy National Cheng Kung University Université Paris-Saclay National Institute of Oncology

About

Wen-Pin Su is an author at National Cheng Kung University Hospital specializing in oncology, medicine, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	8	1.3K
2	Health Sciences	1	1	47
3	Cell Biology	1	1	43
4	Pharmacology	1	1	43
5	Cancer Cell Biology	1	1	43

Wen-Pin Su

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, The Lancet Oncology UrologyOncologyMetastatic Urothelial CarcinomaGenitourinary CancerCancer Management	2022	162
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park, Annals of Oncology Metastatic Urothelial CancerUrologyGenitourinary CancerSelect Fgfr AlterationsMedicine	2023	69
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer. Thomas Powles, Juergen E. Gschwend, Yohann Loriot, Journal of Clinical Oncology Cisplatin-ineligible PtsTps4590 BackgroundUrologyChemotherapy Versus ChemotherapyAdvanced Bladder Cancer	2017	47
Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells Wen-Pin Su, Ya-Chin Lo, Jin‐Jou Yan, Carcinogenesis Cell DeathCancer BiologyTumor BiologyOxidative StressCancer Cell Biology	2012	43
BMP2 promotes lung adenocarcinoma metastasis through BMP receptor 2-mediated SMAD1/5 activation Cheng-Kuei Wu, Man-Ting Wei, Hung‐Chang Wu, Scientific Reports	2022	30
HER-2/neu raises SHP-2, stops IFN-γ anti-proliferation in bladder cancer Wen-Pin Su Biochemical and Biophysical Research Communications UrologyOncologyGenitourinary CancerMedicineCancer Biology	2007	10

Page 1